Abstract: The present invention relates to a composition for screening antihypertensive drugs, which contains a mammalian TCTP gene or a protein expressed therefrom, as well as a method for screening antihypertensive drugs using the composition. TCTP contained in the inventive composition acts as a cytoplasmic inhibitor of the Na/K APTase pump, thus causing hypertension and heart hypertrophy. Therefore, the inventive composition and the screening method using the same will be useful for the investigation and development of antihypertensive drugs. Furthermore, the inventive TCTP-overexpressing transgenic mice shows hypertension or heart hypertrophy as a phenotype. Thus, the inventive transgenic mice will be useful in screening test substances developed for the treatment and improvement of hypertension and heart hypertrophy, by administering the test substance to the transgenic mice and observing the extent of treatment and improvement.
Type:
Application
Filed:
June 16, 2004
Publication date:
June 12, 2008
Applicant:
EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION
Inventors:
Kyung-Lim Lee, Goo-Taeg Oh, Myeong-Chan Cho, Min-Jeong Kim
Abstract: The present invention relates to 1-/2-substituted-1H/-2H-[1,2,3]triazolo[4,5-g]phthalazine-4,9-dione compounds and their pharmaceutically acceptable salts, a process for preparing the compounds and a pharmaceutical composition comprising the compounds. The compounds are shown to effectively inhibit cell proliferation and are thus expected to be used for treatment or prevention or treatment of various cancers or as an ancillary(auxiliary) means of the same.
Type:
Grant
Filed:
January 12, 2006
Date of Patent:
January 9, 2007
Assignee:
EWHA University-Industry Collaboration Foundation
Inventors:
Hea Young Park Choo, Jin Sung Kim, Hee Kyung Rhee, Hyun Joo Park, Sang Kook Lee, Chong Ock Lee
Abstract: The present invention relates to 1-/2-substituted-1H/-2H-[1,2,3]triazolo[4,5-g]phthalazine-4,9-dione compounds and their pharmaceutically acceptable salts, a process for preparing the compounds and a pharmaceutical composition comprising the compounds. The compounds are shown to effectively inhibit cell proliferation and are thus expected to be used for treatment or prevention or treatment of various cancers or as an ancillary(auxiliary) means of the same.
Type:
Application
Filed:
January 12, 2006
Publication date:
September 28, 2006
Applicant:
EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION
Inventors:
Hea Young Choo, Jin Kim, Hee Rhee, Hyun Park, Sang Lee, Chong Lee
Abstract: The present invention relates to IgE-dependent histamine releasing factor (HRF) and HRF-binding peptides, more precisely, deletion forms of HRF which are able to be formed as dimers containing amino acid sequence represented by SEQ ID NO:3, genes encoding thereof and novel HRF-binding peptides having an activity of inhibiting HRF. The deletion forms of HRF which are able to be formed as dimers of the present invention induces intracellular secretion of histamine and IL-8, making an excellent candidate for a drug for inhibiting allergic reaction triggered by HRF and a kit for detecting HRF in serum of an allergy patient. In addition, novel HFR-binding peptides of the present invention bind to HRF to inhibit the actions of HFR, so they can be effectively used for the prevention and the treatment of allergic diseases of animals including asthma and rhinitis or malaria.
Type:
Application
Filed:
January 25, 2006
Publication date:
July 27, 2006
Applicant:
EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION
Abstract: The present invention relates to a thermosensitive and biocompatible poly(organophosphazenes) represented by Formula 1, and a preparation method thereof: wherein x is an integer of 3, 4, 7, 12 or 16; R is methyl, ethyl or benzyl group; R1 is selected from the group consisting of CH2CH(CH3)2, CH2C6H5, CH(CH3)CH2CH3 and CH3; R2 is selected from the group consisting of CH2COOR, CH2CH2COOR, CH2CH(CH3)2 and CH(CH3)CH2CH3; R3 and R4 are independently selected from the group consisting of CH2COOR, CH2CH2COOR and H, wherein said R is the same as defined above; a, b and c are equal to 1, respectively; and d and e are 0 or 1.
Type:
Application
Filed:
October 14, 2005
Publication date:
April 20, 2006
Applicant:
EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION
Inventors:
Youn Sohn, Hae Kim, Jin Kim, Hye Kim, Yong Jun, Udaya Toti
Abstract: The present invention relates to a thermosensitive and biocompatible poly(organophosphazenes) represented by Formula 1, and a preparation method thereof: wherein R is a methyl or ethyl group; R? is selected from the group consisting of COOR, CH2COOR, CH2CH2COOR, CH2CH(CH3)2, CH2C6H5, CH(CH3)CH2CH3 and CH3; R? is selected from the group consisting of CH2COOR, CH2CH2COOR, CH2CH(CH3)2, CH2C6H5, CH(CH3)CH2CH3 and CH3; R?? is a group selected from the group consisting of CH2COOR, CH2CH2COOR and H, wherein R is the same as defined above; n is a number between from 30 to 100; x is a number selected from the integers of 3, 4, 7, 12 and 16; y is a number between from 0.5 to 1.5; a equals to 1; and b and c equal to 0 or 1.
Type:
Application
Filed:
September 20, 2005
Publication date:
March 23, 2006
Applicant:
EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION
Inventors:
Youn Soo Sohn, Ji Jeon Seong, Yong Jun, Joo Kim
Abstract: Compounds of the formula: wherein R1, R2, R3, A1 and A2 are as defined herein, which are used advantageously in inhibiting the TGF-? and/or activin signaling pathway in mammals.
Type:
Application
Filed:
November 8, 2004
Publication date:
November 24, 2005
Applicants:
IN2GEN CO., LTD., SK CHEMICALS CO., LTD., Ewha University Industry Collaboration Foundation
Inventors:
Dae-Kee Kim, Yung-Jue Bang, Hun-Taek Kim, Il-Snag Cho, Myoung-Soon Park, Young An, Joon Choi